Veru Application OKd on Phase 2b for Muscle Loss Associated with Weight Loss Drugs

 FDA IND clearance is an important development milestone in advancing enobosarm in combination with GLP-1 drugs for potentially higher quality weight loss than has been shown with GLP-1 drug alone

Randomized Phase 2b clinical trial aims to show enobosarm preserves muscle and physical function while augmenting fat loss in sarcopenic obese or overweight elderly patients on GLP-1 drug for weight loss

Phase 2b clinical trial is expected to initiate by April 2024

Phase 2b clinical trial final topline results are anticipated by year-end

https://www.globenewswire.com/news-release/2024/02/06/2824317/11676/en/Veru-Announces-FDA-Clearance-of-IND-Application-to-Initiate-Phase-2b-Clinical-Trial-with-Enobosarm-to-Treat-Muscle-Loss-Associated-with-Weight-Loss-Drugs.html